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CD8+ T cells play a critical role in protective immunity against Hepatitis B Virus (HBV). Epitope-based DNA vaccines expressing HBV-
dominant CTL epitopes can be used as candidate vaccines capable of inducing cytotoxic T Lymphocytes (CTL) responses. A plasmid DNA
encoding a CTL epitope of HBV core antigen, HBc18–27, was constructed. Intramuscular immunization of C57BL/6 mice with this DNA
vaccine resulted in successful induction of HBV-specific CTL responses. In order to promote transportation of the peptide into endoplasmic
reticulum (ER) to bind to MHC class I molecules for optimal class I antigen presentation, an ER targeting sequence (ERTS) was fused with
the C18–27 encoding gene. ERTS fusion significantly enhanced specific CD8
+ T cell responses in terms of CTL cytolysis as well as IFN-g
secretion. This enhancement was correlated with promoted epitope presentation on target cell surface. We report here an enhanced
immunogenicity of an epitope-based DNA vaccine using an ER targeting signal sequence, which has significant implications for future
design of therapeutic HBV vaccine.
D 2005 Elsevier Inc. All rights reserved.
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Delivery of plasmid DNA into living animals leads to
expression of the protein of interest in vivo and effective
induction of both humoral and cellular immunity to the
expressed protein. Especially the ability of DNA vaccine to
induce specific CTL responses makes it a promising
candidate to confer protection against viral infections and
tumor challenges (Nagata et al., 2004).
Most currently available vaccines including DNA vac-
cines are based on dnaturalT forms of various pathogens or
selected antigenic components of the pathogen. Although0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.01.040
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E-mail address: sdxiongfd@126.com (S. Xiong).effective against some pathogens, they have thus far been
unable to deal with most types of tumors and chronic viral-
infectious diseases, such as caused by HIVand HBV. One of
the possible reasons may lie in that whole protein antigen is
composed of various epitopes, and that dominant epitopes
usually determine the immunogenicity of the whole protein.
Therefore, antigenic variation of a specific epitope can result
in immune escape (Chen and Oon, 1999; Klenerman and
Zinkernagel, 1998; Rimmelzwaan et al., 2004). While
irrelevant or suppressive epitopes within the same protein
could interfere with the function of dominant epitopes, as a
result making whole protein vaccine generate unwanted
responses such as antibody-mediated enhancement of viral
diffusion (Takada and Kawaoka, 2003). Meanwhile, CTL
responses to a dominant epitope can recognize potential
epitope variants which are absolutely requested for vaccines
design against highly-mutating viruses (Charini et al.,05) 255–263
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within a protein and development of CTL epitope-based
vaccines could be promising to counteract chronic viral
diseases (Goulder et al., 2000; Zhong et al., 2003). Single or
multi-epitopes-based DNA vaccines have been successfully
developed since 1996 resulting in efficient induction of
epitope-specific cytotoxic T lymphocytes (CTLs) against
various pathogens (Ciernik et al., 1996; Lindinger et al.,
2003; Nakamura et al., 2003; Subbramanian et al., 2003).
However, their capabilities to elicit potent immune
responses need to be improved, since the immunogenicity
of an epitope is usually poor.
Chronic viral hepatitis caused by Hepatitis B virus
(HBV) infection remains a significant world health problem.
HBV-specific CTLs play a crucial role in the control of
HBV infection, through direct lysis of virus-infected cells
and release of cytokines at the site of infection (Bertoletti et
al., 1997; Guidotti et al., 1999). Most importantly, effective
HBV-specific CD8+ T cell responses proved to inhibit virus
replication independent of liver damage (Maini et al., 2000a,
2000b) while inadequate CTL responses and nonantigen-
specific T cells infiltration might contribute to liver
pathology (Bertoletti and Maini, 2000). Therefore, it is vital
to stimulate or boost HBV-specific CTLs for design of
prophylactic or therapeutic HBV vaccines. And the relative
contribution of virus-specific CTLs to viral control may be
significantly determined by their epitope specificity (Web-
ster and Bertoletti, 2001).
When strong HBV core antigen (HBc)-specific CTLs
could be always detected lysing infected hepatocytes during
the recovery period of acute HBV infection, their reduction
or even absence in chronic infection indicates an important
correlation of protection with HBc antigen. Therefore, HBc
protein-based DNA vaccines have been largely evaluated its
ability to induce specific CTL responses (Bo¨cher et al., 2001;
Kwissa et al., 2000; Thermet et al., 2004). Moreover, mutant
viruses may evade immune system due to the loss of a CTL
epitope within the HBc gene indicating a dominant CTL
epitope could determine the immunogenicity of the HBc
antigen (Lee et al., 2001). C18–27(FLPSDFFPSV), an HBc-
derived CTL epitope, represents so far the most dominant
CTL epitope within the HBV genome (Maini et al., 2000a,
2000b). ~N90% of HLA-A2-positive patients with acute
HBV infection produce a CTL response against HBc18–27,
which is not detectable in HLA-A2-positive patients with
chronic hepatitis, suggesting that a vigorous CTL response to
this epitope may contribute to viral clearance during HBV
infection (Missale et al., 1993). HBc18–27 epitope can bind to
and prime different HLA-A2 subtypes (Maini et al., 2000a,
2000b; Missale et al., 1993) and it could activate HLA class
II restricted HBc-specific T-cell response which plays a
central role in anti-HBV immunity (Bertoletti et al., 1997).
Based on these premises, C18–27 was selected as the target
gene of our epitope-based DNA vaccine; we reasoned that
focusing CTL responses to this dominant epitope would be
very helpful for HBV clearance.Since CTL induction requires endogenous peptides
loaded onto major histocompatibility complex (MHC) class
I molecules on surfaces of antigen-presenting cells (APCs)
and target cells, peptide transport into the endoplasmic
reticulum (ER) is therefore very critical where it is
complexed with newly synthesized MHC class I molecules
(Moron et al., 2004). To target CTL epitopes into the ER,
the C18–27 coding gene was fused with an ER targeting
signal sequence (ERTS) derived from the Adenovirus E3
leader sequence which has been demonstrated to facilitate
epitope transport into ER and therefore enhance specific
immunity induction (Anderson et al., 1991; Ciernik et al.,
1996; Restifo et al., 1995).
Here, we report an epitope-based DNA vaccine targeted
against the HBc18–27 peptide and demonstrate its efficacy in
inducing specific CTL responses against HBV in an H-2b
mouse model. Furthermore, an ER targeting signal sequence
(ERTS) was inserted upstream the C18–27 sequence in order
to promote CTL induction by enhancing intracellular
antigen presentation efficiency.Results
Construction of pECK-C18 and pECK-E3-C18
A modified plasmid expression vector containing hCMV
IE1 promoter, BGH polyA signal sequence was constructed
as pECK. Oligonucleotides coding for a CTL epitope,
HBc18–27, were synthesized and cloned into pEC
K, yielding
plasmid pECK-C18 (Fig. 1A). Fusion of ER targeting
sequence derived from adenovirus E3 leader sequence in
frame with C18–27 gene generated plasmid pEC
K-E3-C18
(Fig. 1B).
Epitope expression in vitro
In vitro transfection efficiency of pECK-C18 was eval-
uated in C2C12 skeletal muscle cells. FuGENE
TM 6–DNA
complex was used to transfect C2C12 cells. Peptide
expression in the culture supernatant was analyzed by Dot
Immunoblot Assay. C18–27 peptide expression reached a
maximum around 24 h after transfection, then decreased
slightly, still had 50% of the maximum expression at 72 h
(Fig 2). In vitro expression of pECK-C18 showed that
transfectants secreted transgenic peptides at 24, 48 and 72 h
posttransfection, implying that C18–27 epitope cloned in
pECK was correctly transcripted, translated, and secreted.
Fusion of ER targeting sequence with C18–27 encoding gene
hardly changed the expression kinetics of C18–27 epitope.
Induction of C18–27-specific CTL responses by
C18–27-based DNA vaccine
To demonstrate whether the C18–27 CTL epitope cloned
in pECK vector was immunogenic, 6- to 8-week-old
Fig. 1. Schematic presentation of pECK-C18 and pECK-ERTS-C18 plasmid.
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with two doses of 100 Ag pECK-C18 DNA. Mice inoculated
with empty pECK DNA were used as control. 10 days after
the last immunization, splenocytes were isolated and
expanded as CTLs by in vitro stimulation with C18–27
peptides-pulsed syngeneic feeder cells for 6 days. They
were then tested for cytolytic activity against 51Cr labeled
EL4 cells prepulsed with or without C18–27 peptide. Under
these test conditions, only peptide-pulsed EL4 cells were
lysed; whereas no or low lysis was detectable using EL4 or
HBs208–215 control peptide-pulsed EL4 as target cells
indicating CTLs were successfully generated and were
C18–27 specific. The cytolysis of non-restimulated spleno-
cytes was very low, only 2.83% and 0.4% for pECK-C18
and pECK-immunized mice at E/T ratio 10/1 (figure not
shown).
Cytotoxic assay showed that intramuscular delivery of
pECK-C18 into C57BL/6 mice resulted in efficient induction
of CTLs specific against HBV core antigen. The specific
cytolysis amounted to 16.21% at E/T ratio 10:1 compared to
2.48% for control mice (Fig. 3).Fig. 2. In vitro C18–27 peptide expression after DNA transfection. 2 Ag
DNA complexed with FuGENE6 were added to C2C12 cells, and
synthesized C18–27 peptide was used as positive control. Expressed peptides
in the supernatant were detected by DIA 24, 48, and 72 h posttransfection.
(A) pECK-E3-C18 transfected C2C12 cell supernatant; (B) pEC
K-C18
transfected C2C12 cell supernatant; (C) pEC
K transfected C2C12 cell
supernatant; (D) C18–27 peptide.C18–27-specific CTL responses are enhanced by upstream
fusion of ERTS with C18–27
To further investigate whether ER targeting signal
sequence (ERTS) fusion could effectively enhance the
immunogenicity of C18–27 encoding gene, two doses of
100 Ag pECK-E3-C18 DNA were intramuscularly adminis-
trated to C57BL/6 mice. C18–27-specific CTL responses in
mice immunizedwithDNAconstruct harboring ERTS-C18–27
fusion gene were significantly higher than that in mice
treated with DNA containing C18–27 gene only (P b 0.05).
Specific cytolysis of CTLs derived from pECK-E3-C18-,
pECK-C18-, and pEC
K-immunized mice were 24.06%,
17.20%, and 0.048%, respectively at E/T ratio 10:1 (Fig. 4).
Enhancement of CTL epitope immunogenicity is correlated
with increased amounts of presented peptides
If the variation of the immunogenicity of C18–27 epitope
associated with or without ERTS was the result of different
efficiencies of the CTL epitope binding to MHC I moleculeFig. 3. Immunogenicity of C18–27 epitope-based DNA vaccine in C57BL/6
mice. C57BL/6 mice were intramuscularly immunized with two doses of
pECK (circles) or pECK-C18 (squares) DNA with 3 weeks intervals. 10
days after the last immunization, splenocytes were isolated and stimulated
with C18–27-pulsed syngeneic feeder cells in vitro for 6 days and used as
effector cells. Cytotoxicity was assayed in a 51Cr release assay against EL4
target cells in the presence (filled symbols) or absence (open symbols) of
C18–27 peptide. *P b 0.05.
Fig. 5. T cell proliferative responses to C18–27 peptide presented on surfaces
of target cells. Splenocytes stimulated with C18–27-pulsed syngeneic feeder
cells in vitro for 6 days were incubated with mitomycin-treated EL4 cells
(5), mitomycin-treated EL4 cells transfected the day before with pECK-
C18 (q) or pECK-E3-C18 (n) DNA. ConA stimulation ( ) was used as a
positive control. Each bar represents the average values of 3 mice,
measured in duplicate. * a: P = 0.0024 compared to pECK-C18 transfected
EL4 stimulation of pECK-C18 immunized mice; * b: P = 0.0222 compared
to pECK-C18 transfected EL4 stimulation of pECK-E3-C18-immunized
mice.
Fig. 6. IFN-g production of in vitro restimulated splenocytes. Splenocytes
derived from pECK- (5), pECK-C18 (q) or pECK-E3-C18 (n) immunized
mice were restimulated in vitro with C18–27-pulsed syngeneic feeder cells
for 96 h before the culture supernatants were collected and tested for IFN-g
levels by ELISA Assay. *P b 0.05.
Fig. 4. HBc-specific CTLs induced by pECK-E3-C18 DNA vaccine.
Splenocytes from immunized mice were stimulated with C18–27-pulsed
syngeneic feeder cells for 6 days and tested for cytotoxic activity in a 4-h
51Cr release assay against allogeneic EL4 targets prepulsed with (filled
symbols) the same peptide or without (open symbols). The E/T ratio used
was 80:1 to 10:1. Representative CTL responses induced by pECK
(triangle), pECK-C18 (circles) and pECK-E3-C18 (squares) DNA immuni-
zation were indicated. *P b 0.05.
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should be detectable in cells transfected with different DNA
constructs. To test this idea, EL4 cells were transfected with
empty vectors, DNA vectors expressing either C18–27 or
ERTS-C18–27 fusion protein for 24 h and served as
stimulators. Splenocytes from pECK-E3-C18-, pEC
K-C18-,
or pECK-immunized mice were restimulated in vitro with
C18–27 peptides and used as responders. Specific prolifer-
ation assays were conducted showing that SI of splenocytes
stimulated with pECK-E3-C18-pretransfected EL4 was sig-
nificantly greater than that of splenocytes stimulated with
pECK-C18-pretransfected EL4 (P = 0.0024 and P = 0.0222
for pECK-C18 and pECK-E3-C18 immunization group,
respectively), indicating that fusion of ERTS increased
antigen presentation levels effectively (Fig. 5). This result
was paralleled with the elevated CTL responses induced by
pECK-E3-C18 vaccine indicating that an ER targeting
sequence at the amino-terminus of a CTL epitope could
enhance the immunogenicity of the epitope through elevat-
ing epitope presentation efficiency.
It is unlikely that this difference in C18–27 presentation is
attributed to differences in gene expression among stimulator
cells, since C18–27 peptide expression in EL4 cells 24 h after
DNA transfection showed no significant difference whether
fused or not with ERTS (Fig. 2).
ERTS contributed to increased IFN-c production by
restimulated T cells
Since HBc18–27-based DNA vaccine was demonstrated
effective to induce strong C18–27-specific CTL responses,
specific Th1 responses generated by this DNA vaccine were
also evaluated in an IFN-g secretion assay. In vitro
restimulated splenocytes from mice immunized with variousDNA constructs were tested for their ability to secrete IFN-g
into the culture supernatant. It was found that restimulated T
cells derived from pECK-E3-C18-immunized mice produced
at least 2 times higher levels of IFN-g than those derived
from pECK-C18-treated mice (Fig. 6), confirming that ERTS
fusion at the amino terminus of the CTL epitope could
largely increase epitope-specific CD8+ T responses induced
by our CTL epitope-based DNA vaccine.Discussion
By virtue of the sustained in vivo antigen synthesis and
the comprised stimulatory CpG motifs, DNA vaccine is
known for induction of a full range of immune responses,
including neutralizing antibodies and CTLs, resulting in
anti-pathogen protection. Substitution of whole protein
encoding gene with specific epitope encoding sequence is
an alternative way to improve immunological focusing and
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vaccines with increased safety, the opportunity to rationally
engineer epitopes for increased potency and breadth, and the
ability to focus immune responses on conserved epitopes
(Sette and Fikes, 2003).
The ability of CD8+ T cells to directly recognize virus-
infected cells and activate anti-viral pathways in the infected
hepatocytes through secretion of cytokines makes these cells
the obvious candidate for expansion through a vaccine
therapy for HBV infection (Webster and Bertoletti, 2001).
CTL responses also play an important role in limiting virus
replication without causing inflammatory disease (Bertoletti
et al., 2003). Therefore, induction of CTL responses specific
against HBV represents a promising strategy to protect
against HBV infection. However, current widely used HBV
vaccines for humans, whole-killed, subunit vaccines, or
recombinant protein, are processed solely as exogenous
antigens, and often result in poor induction of cell-mediated
immunity (Davis and McCluskie, 1999), therefore limiting
their use in therapeutic applications. Synthetic polypeptide
vaccine owns poor immunogenicity and high cost of
manufacturing. Moreover, adjuvant as Alum (currently
licensed for human use) for protein-based vaccine has a
strong Th2 bias that dramatically abrogates CTL responses
(Petrovsky and Aguilar, 2004). Therefore, a CTL epitope-
based DNA vaccine seems to have many advantages over
traditional protein-based vaccines with regard to CTLs
induction. It has become a promising approach for prophy-
laxis and therapy of hepatitis B (Thermet et al., 2003).
Here, we reported the intramuscular immunization of
C57BL/6 mice with a CTL epitope-based DNA vaccine
carrying a minigene coding for a single CTL epitope, C18–27,
derived from HBV core protein and demonstrated its efficacy
to induce HBV-specific CTLs. We reasoned that this highly
conserved CTL epitope, rather than the whole protein, is
more rational for CTL induction.
However, the specific cytolysis of CTLs induced with
DNA construct with C18–27 gene only is not very high in our
study. One reason is that the immunogenicity of an epitope
lacking necessary flanking residues is usually poor, even in
the form of DNA vaccine. The other reason might be that
C18–27 was discovered as an HLA-A2-restricted peptide, not
an H-2b-restricted peptide. Since peptide binding with an
appropriate MHC molecule could influence the immuno-
dominance of the peptide (Takada and Kawaoka, 2003), the
species-specificity of the peptide binding to MHC molecules
has become a challenge in the development of epitope-based
vaccines (Moron et al., 2004). So we compared the amino
acid sequence of C18–27 with that of H-2D
b/H-2Kb binding
CTL epitopes reported to date, natural, or predicted
(Engelhard, 1994; Kuhober et al., 1996; Schirmbeck et al.,
1998; Zhong et al., 2003). The carboxyl-terminal peptide
residue is an important determinant of peptide-MHC I
molecule binding. Most H-2Db or H-2Kb molecules favor
aliphatic residues like I, L, sometimes V (Zhong et al., 2003)
as the carboxyl-terminal peptide residue (P8/9/10). P2residues are also important for the binding; G, L and S are
most often seen at this position. Furthermore, amino acid at
position 5/6 (P5/6) is highly conserved and acts as a strong
determinant of peptide-MHC I binding. H-2Kb molecule
prefers CTL epitopes with F or Y residue at P5. Therefore,
C18–27 epitope (FLPSDFFPSV) possesses L at P2, F at P6
and V at P10 which makes it a potential H-2b-binding
epitope. HBc92–100 peptide (NMGLKFRQL) and HBs208–215
peptide (ILSPFLPL) were reported as both immunodomi-
nant H-2Kb-restricted epitopes (Kuhober et al., 1996;
Schirmbeck et al., 1998). The former possesses F and L at
P6 and P9, the latter has L at P2, F at P5, and L at P8. Both of
them hold similar amino acid compositions as HBc18–27
does. Finally, it was experimentally demonstrated by us that
it bound to murine (H-2b) MHC class I molecules to a
sufficient level to induce HBc-specific T cell responses in
C57BL/6 mice (H-2b). Therefore, poor immunogenicity of
the HBc18–17 epitope is the reason for low CTLs induction by
our C18–27 epitope-based DNA vaccine.
In order to increase the potency of single epitope-based
vaccine, a variety of methods have been described effective
to enhance anti-virus or anti-tumor immunity, including the
selection of the most immunodominant epitope (Melief et
al., 2002), the use of long peptides (Zwaveling et al., 2002),
the combination of CTL epitope with an Th epitope (Baird
et al., 2004) or with co-stimulatory molecules (Shankar et
al., 2001) and use of various adjuvants (Andersen et al.,
2000). A complementary approach entails the direct
delivery of vaccine into intracellular compartments associ-
ated with MHC class I or class II molecules, as a means to
increase epitope uptake as well as epitope presentation in
APCs or the target cells (Takada and Kawaoka, 2003).
Special targeting genes or leader signal sequences derived
from viral genomes have been largely employed to this aim
by mimicking the highly efficient infection process of
viruses. HIV tat antigen helped delivery of antigen into
lysosome (Chikh et al., 2001), and Influenza virus HA-
derived amphipathic polypeptides have been used to direct
cytosolic localization of the antigen which is necessary for
CTL induction (Plank et al., 1994).
Targeting antigens into the MHC class I-restricted
presentation pathway is a prerequisite for the induction of
CTL responses, there are two distinct routes by which a
CTL peptide gains access to MHC class I molecules
(Gromme and Neefjes, 2002). The first involves proteasome
degradation and transportation via TAP into ER; and the
second invokes a proteasome- and TAP-independent ER-
targeting pathway (Leifert et al., 2004). Therefore, targeting
peptides into ER might be a promising means to increase
CTLs induction by the epitope-based DNA vaccine.
Several studies have shown that specific signal
sequences at the N-terminus of a protein could facilitate
its entry into ER in a TAP-independent manner and its
eventual presentation on the cell surface, where it can be
recognized by CD8+ T cells (Anderson et al., 1991;
Bacik et al., 1994; Rice et al., 1999). In particular, an
W. Xu et al. / Virology 334 (2005) 255–263260ER-targeting sequence derived from the adenovirus E3
leader sequence was demonstrated to enhance CTL
responses induced by a DNA vaccine harboring mutant
p53 or HIV gp120 encoding gene (Ciernik et al., 1996).
In our study, a similar ER-targeting signal sequence was
fused with the HBc18–27 epitope encoding gene, and an
enhancement of CTL induction due to promotion of
epitope presentation was again validated. Besides, a C-
terminal KDEL sequence derived from some toxins, also
called ER retrieval signal, could efficiently target
exogenous peptides into ER lumen therefore enhance T
cell immune responses (Lee et al., 1998).
Other strategies proposed to enhance delivery of CTL
epitopes into the MHC I antigen presentation way include
orienting protein delivery towards the proteasome (Rodri-
guez et al., 1998), promoting translational ubiquitination of
the antigen (Wu and Kipps, 1997), and the use of other
functional protein domains capable to enhance the class I
epitope presentation. A GMI-binding B subunit of Escher-
ichia coli heat-liable toxin (EtxB) was reported to improve
the class I epitope presentation when conjugated to either of
the two immunodominant MHC I epitopes (De Haan et al.,
2002). All these strategies to direct CTL epitopes into class I
antigen processing and presentation way resulted in
successful enhancement of CTLs induction or Th1 immune
responses as has also been demonstrated by our study.
In our study, the enhanced induction of CTLs could be
probably ascribed to the promotion of epitope presentation
on surface of target cells or APC by the ERTS which was
fused to the CTL peptide, since pECK-E3-C18 transfected
EL4 cells stimulated more expanded T cells to proliferate
than pECK-C18 transfected EL4 cells did (Fig. 5). These
data also support the belief that the immunogenicity of a
CTL epitope in DNA vaccine can be optimized by
improving the level of epitope presentation (Livingston et
al., 2001). Other possible strategies to increase epitope
presentation include viral vector usage and modulation of
flanking residue of specific CTL epitopes (Moron et al.,
2004).
Interferons are the most effective available drugs for
treatment of chronic HBV infection (Lee et al., 2001). It
has been demonstrated that successful CTL responses use
a noncytopathic mechanism of viral clearance to com-
pletely abolish HBV replication mainly by secreting
cytokines IFN-g and TNF-a (Bertoletti and Maini,
2000). These two cytokines are able to selectively degrade
replicating genomes of HBV. To evaluate the potential of
CTLs to produce IFN-g, in vitro expanded CTLs after 96
h of specific stimulation were tested for their ability to
secrete IFN-g in the culture supernatant. As expected,
IFN-g secretion was largely increased in mice immunized
with DNA harboring C18–27 gene compared with the
vector control and reached the highest level in mice
treated with ERTS-C18–27 fusion gene vaccine. These
results indicate that the CTL epitope-based DNA vaccine
we constructed not only induces successful HBc-specificCD8+ T cell responses, but also has a therapeutic
potential.
In this study, we have devised a genetic epitope vaccine
vector that allows the efficient expression of the HBc-
derived C18–27 CTL epitope, resulting in the successful
induction of HBV-specific cellular immunity, which was
further improved by an N-terminal fused ER-targeting
sequence. Our CTL epitope-based DNA vaccine may thus
have a great potential as a future prophylactic or even
therapeutic HBV vaccine.Materials and methods
Animals
Female C57BL/6 mice, 6–8 weeks old, were obtained
from Laboratory Animal Centers (Fudan University, Shang-
hai). The mice were housed under specific pathogen-free
conditions. Treatment of the animals conformed to the
ARVO Statement on the Use of Animals in vaccine
research.
Plasmids and primers
pECK plasmid DNA vector was derived from pUC19
plasmid (Invitrogen) and modified by adding HCMV IE1
promoter/enhancer complex and BGH polyA sequence.
Oligonucleotide GATCT GCCAC CATGT TTTTG CCTTC
TGACT TCTTT CCTTC TGTTTAGTAA coding for the aa
18–27 of HBc antigen, with additional KOZAK, ATG and
double stop codons, and its antisense analogue were
synthesized, annealed and inserted into the BglII site of
pECK vector thus generating pECK-C18 plasmid. To
construct the inserts for pECK-E3-C18, the following
oligonucleotides were annealed, extended with Klenow
and dNTPs, and amplified by PCR: 5V-GAAGA TCTGC
CACCA TGAGG TACAT GATTT TAGGC TTGCT
CGCCC TTGCG GCAGT CTGCA GCGCT GCCTT
TTTGC CTTCT GACTT C-3V and 3V-CGGAA GACTG
AAG AA AGGAA GACAAATCATT CTAGA AG-5V. The
resulting oligonucleotide duplexes encoding for C18–27
peptide preceded by ER targeting sequence/ERTS (adeno-
virus E3 leader sequence) were digested with BglII and
cloned into the unique site BglII of pECK, resulting in
pECK-E3-C18 plasmid. All inserts were sequenced after
construction. Endotoxin-free plasmids were obtained using
Endofree plasmid mega kit (Qiagen, Germany).
Cells, peptides and antibodies
C3H C2C12 skeletal muscle cell is a gift from Prof.
Maurizio Zanetti (UCSD, USA). C57BL/6 EL4 (H-2b)
thymic lymphoma cells were obtained from ATCC.
HBc18~27 peptide with amino acid sequence FLPSDEFPSV
was synthesized (Sbsbio Co Ltd., P.R. China).
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5  105 C2C12 cells were transfected with 2 Ag of
plasmid DNA in 6-well plate at 37 8C and 5% CO2 in RPMI
1640 containing non-serum, 2 mM l-glutamine, 100 U/ml
penicillin, and 100 U/ml streptomycin for 48 h, followed by
changing the medium to fresh complete medium (1640
containing 10% FBS). Cells were cultured for 3 days before
assay. Transfection of pECK, pECK-C18 and pECK-E3-C18
using FuGENE 6 (Boehringer Mannheim) was carried out to
the manufacturer’s protocol. C18–27 synthesized peptide was
used as a positive control.
Peptide detection by dot immunoblot assay
Peptide detection was carried out using a dot immunoblot
assay according to standard protocols (Loi et al., 1997). 20
Al of cell culture supernatants were spotted onto a 0.22-Am
nitrocellulose membrane (Amersham). The membrane was
air dried at room temperature and fixed at 37 8C for 60 min.
After washing, it was incubated for 60 min in a blocking
solution containing 0.3% bovine serum albumin (BSA) in
0.1 M Tris buffer (pH 7.4). Then, it was incubated overnight
with rabbit-anti-HBc polyclonal antibody (Dako, USA),
followed by a biotinylated secondary antibody (VECTAS-
TAIN ABC Reagents, USA) for 30 min. The membrane was
then transferred to a solution of streptavidin peroxidase for
30 min and revealed by DAB substrate. The spot was taken
as photographs, scanned into computer, and adjusted for
equal brightness and contrast using PhotoShop.
DNA intramuscular immunization
For DNA immunization, groups of 6–8-week-old
C57BL/6 (n=6) mice were pretreated by injecting 100 Al
of 0.25% bupavokein (Sigma, St. Louis, MO) into the
tibialis anterior muscle. After 24 h, the same muscle was
injected with 100 Ag plasmid DNA diluted in phosphate
buffer saline (PBS) and boosted with 100 Ag DNA 3 weeks
later. For CTL assays, mice were sacrificed 10 days after the
second immunization.
CTLs expansion in vitro
CTLs were prepared from spleens of DNA immunized
C57BL/6 and used either directly or after 6 days restim-
ulation in vitro in CTL assay. Splenocytes were resuspended
in RPMI 1640 medium containing 10% FBS, antibiotics and
l-glutamine. Feeder cells were syngeneic spleen cells
depleted of erythrocytes, subjected to 20 Gy of irradiation,
resuspended in RPMI 1640 containing 20 Ag/ml C18–27
peptide, incubated for 2 h at 37 8C, washed, and resuspended
in RPMI 1640 at a concentration of 1  106/ml. CTLs were
obtained by culturing 5  106 immune splenocytes with
1  106 feeder cells in flat-bottom 24-well tissue culture
plates for 6 days, where the medium supplied with IL-2 to afinal concentration of 20 U/ml was changed at 2- to 3-day
intervals. For in vitro restimulation, splenocytes from
C57BL/6 mice stimulated with an irrelevant Kb-restricted
control peptide derived from HBsAg208–215 (ILSPFLPL) did
not generate cytolytic responses above background level.
CTL assay
A standard chromium release assay was used to
monitor CTL activity. Briefly, 5  106 EL4 (H-2b) cells
were labeled with 7.4  106 Bq 51Cr (Amersham, USA)
for 1.75 h then pulsed with 20 Ag/ml C18–27 peptide for
2 h at 37 8C and used as target cells. They were mixed
at appropriate ratios with restimulated effectors in
duplicate and incubated at 37 8C for 4 h. Supernatants
were harvested and radioactivity was counted in a gamma
counter (LKB, Gaithersburg, MD). Each animal was
analyzed independently. Percent-specific lysis was calcu-
lated using the equation: 100  [(experimental release 
spontaneous release) / (maximum release  spontaneous
release)]. Results are presented as peptide-specific lysis,
calculated by subtracting the percent specific lysis of
control EL4 target cells from the percent specific lysis of
the peptide-pulsed EL4 target cells at the same E/T ratio.
Spontaneous release was determined by incubating
labeled target cells with RPMI 1640 and ranged between
10 and 15% in various experiments. Maximum release
was determined by lysing the target cells with 5% SDS.
Lymphocyte proliferation
In vitro stimulated CTLs (6 days after C18–27-pulsed
syngeneic feeder cells stimulation) were titrated into 96-
well round-bottomed plates (Costar) at a concentration of
5  106/ml as responder T cells, 1.5  106/ml pECK-E3-
C18-, pECK-C18- or non-transfected (24 h) EL4 cells
were inactivated and used as stimulators. The cultures
were incubated for 72 h at 37 8C in 5% CO2, pulsed
with 3.7  104 Bq [3H]-thymidine (Amersham, USA) per
well during the last 18 h of incubation, and then were
harvested. [3H]-thymidine uptake was determined by
standard liquid scintillation.
IFN-c measurements
IFN-g was determined by enzyme linked immunosorbent
assay (ELISA) according to the manufacturerTs directions
(Pharmingen). Briefly, ELISA plates (Costar) were coated
with R4-6A2, a rat monoclonal antibody specific for murine
IFN-g (Pharmingen) overnight at 4 8C, and then blocked for
2 h at room temperature with 10% fetal bovine serum (FBS)
in PBS. Culture supernatants of splenic cells which had
been restimulated with C18–27 peptide-pulsed feeder cells for
96 h (mentioned above) were added to the plate. After
washing, the second biotinylated monoclonal antibody
specific for murine IFN-g (Pharmingen) was added. HRP-
W. Xu et al. / Virology 334 (2005) 255–263262coupled strepavidin and TMB were used to detect biotiny-
lated antibody. The absorbance is read at 450 nm using
ELX800 ELISA plate reader (Biotek, USA).
Statistical analysis
Data are shown as means and standard deviations;
differences were analyzed by Student’s t test and a
probability of less than 0.05 was taken as significant.Acknowledgments
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